RxDoctor Payments Data
★ My doctorsLook up a doctor →

Maria Ospina

Neurology · Phoenix, AZNPI 1881633212

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,518,064 of the $2,111,824 with a category attached, or 71.9%. 48 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 30.4% of the total. 2025 is the largest year on record at $547,288, 3.0 times the $181,953 reported in 2019. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,111,824in general payments, 2019–2025

Across 3,017 payments — averaging $699.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$643K
  • Amneal Pharmaceuticals LLC$416K
  • MDD US Operations, LLC$291K
  • AbbVie$269K
  • Teva Pharmaceuticals USA, Inc.$254K
  • Kyowa Kirin, Inc.$95K
  • plus $144K from 42 others

What the payments were for

  • Consulting fees$345,82216%
  • Speaking & faculty fees$1,518,06472%
  • Travel & lodging$187,8489%
  • Food & beverage$51,7102%
  • Education$8,3790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.624$642,958
Amneal Pharmaceuticals LLC411$415,563
MDD US Operations, LLC305$290,818
AbbVie(2 entities)500$269,182
Teva Pharmaceuticals USA, Inc.293$254,057
Kyowa Kirin, Inc.129$95,116
Merz Pharmaceuticals, LLC43$52,343
Acorda Therapeutics, Inc126$51,273
Sunovion Pharmaceuticals Inc.32$9,484
Adamas Pharmaceuticals, Inc.19$8,913
Boston Scientific42$5,800
Medtronic(2 entities)75$5,460
Abbott84$4,150
Acadia Pharmaceuticals Inc166$3,421
UCB, Inc.28$446
Lilly USA, LLC23$414
Pfizer19$289
Lundbeck LLC14$289
Amgen(2 entities)9$261
Ipsen Biopharmaceuticals, Inc6$139
AstraZeneca6$130
Avion Pharmaceuticals7$125
Idorsia Pharmaceuticals US Inc2$123
Supernus Pharmaceuticals, Inc.2$115
Vertical Pharmaceuticals, LLC6$97
Avanir Pharmaceuticals, Inc.4$74
Biogen4$67
C2n Diagnostics, LLC2$64
Biohaven Pharmaceutical Holding Company Ltd.3$64
Otsuka America Pharmaceutical, Inc.4$62
Insightec,inc2$57
Novartis3$52
Argenx US, Inc.2$46
EMD Serono, Inc.2$38
Axsome Therapeutics, Inc.1$34
Tonix Medicines, Inc.2$34
Upsher-smith Laboratories LLC2$32
Zyla Life Sciences, Inc.2$32
Noctrix Health, Inc.1$32
GE HealthCare1$25
Greenwich Biosciences, Inc.1$25
Travere Therapeutics, Inc.4$24
Cala Health, Inc.1$20
CSL Behring1$18
Biohaven Pharmaceuticals, Inc.1$17
Promius Pharma LLC1$16
Alfasigma USA, Inc.1$16
Bausch Health US, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,111,824 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa279$451,033
NuplazidPimavanserin Tartrate57$376,522
GocovriAmantadine Hcl95$286,847
Austedo XrDeutetrabenazine14$204,420
InbrijaLevodopa52$168,101
IngrezzaValbenazine Tosylate21$161,411
OngentysOpicapone70$83,948
NeuproRotigotine50$62,016
CrexontCarbidopa/Levodopa46$35,654
Rasagiline Mesylate152$31,772
Carbidopa-LevodopaCarbidopa/Levodopa359$29,769
NourianzIstradefylline14$27,705
NuedextaDextromethorphan Hbr/Quinidine13$19,529
Pramipexole ErPramipexole Di-Hcl26$9,875
Carbidopa-Levodopa ErCarbidopa/Levodopa76$7,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Crexont$415,563$486,686325 claims
Acadia Pharmaceuticals IncNuplazid$3,421$376,52257 claims
MDD US Operations, LLCGocovri$290,818$286,84795 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$642,958$245,35991 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$254,057$204,42014 claims
Acorda Therapeutics, IncInbrija$51,273$168,10152 claims
UCB, Inc.Neupro$446$62,01650 claims
Kyowa Kirin, Inc.Nourianz$95,116$27,70514 claims
Avanir Pharmaceuticals, Inc.Nuedexta$74$19,52913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →